Celgene Reiterates Commitment to Improving Pancreatic Cancer Care in Europe, Through Significant Research and Patient Support Initiatives

BOUDRY, Switzerland--(BUSINESS WIRE)--With pancreatic cancer poised to become the third leading cause of cancer death in Europe, Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ ...

FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.S. Food and Drug Administration (FDA) has accepte...